AC2993

DRUG5 trials

Sponsors

AstraZeneca

Conditions

Diabetes Mellitus, Non-Insulin-DependentDiabetes Mellitus, Type 2Type 2 Diabetes Mellitus

Phase 3

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

CompletedNCT00035984

AstraZenecaDiabetes Mellitus, Non-Insulin-Dependent

Start: 2002-05-31End: 2003-08-31Updated: 2015-02-24

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

CompletedNCT00039026

AstraZenecaDiabetes Mellitus, Non-Insulin-Dependent

Start: 2002-02-28End: 2003-08-31Updated: 2015-02-24

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

CompletedNCT00039013

AstraZenecaDiabetes Mellitus, Type 2

Start: 2002-03-31End: 2003-06-30Updated: 2015-02-24

Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

CompletedNCT00044668

AstraZenecaDiabetes Mellitus, Type 2

Start: 2002-08-31End: 2005-09-30Updated: 2015-02-20

Extension Study for 2993-112

CompletedNCT01789957

AstraZenecaType 2 Diabetes Mellitus

Start: 2002-09-30End: 2004-06-30Updated: 2015-02-24

Related Papers

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01

Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.

2012-07-0143 citations

Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.

2012-05-164 citations